Johnson & Johnson Family of Companies
NEWS
Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.
The beginning of booster vaccines for adults was in news for a long time. Well, CDS authorized it now, and here’s the reason behind the authorization.
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
Johnson & Johnson is planning to break off its consumer products business from its pharmaceutical and medical device businesses. They will become two publicly traded companies.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
JOBS
IN THE PRESS